MedTrace Logo

Rarecells Molecular Biomarkers for Early Detection of Lung Cancer

NCT06546007 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2025-06-11

No results posted yet for this study

Summary

Early diagnosis of lung cancer is a public health priority. Additionally, early detection of recurrences after treatment is crucial for optimizing disease management.

This study seeks to demonstrate the accuracy of the Rarecells ISET® circulating tumor cells DNA (CTC-DNA), combined with circulating tumor DNA (ctDNA), for the early diagnosis of lung cancer.

Conditions

Interventions

DIAGNOSTIC_TEST

CTC-DNA

ctDNA for the analysis of lung cancer mutations in patients with operable tumors.

Sponsors & Collaborators

  • Meditrial Europe Ltd.

    collaborator INDUSTRY

  • Meditrial SrL

    collaborator INDUSTRY

  • Rarecells Diagnostics SAS

    lead INDUSTRY

Principal Investigators

  • Patrizia Paterlini, MD, PhD · Rarecells

Eligibility

Min Age
35 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-13
Primary Completion
2025-06-01
Completion
2025-10-01

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06546007 on ClinicalTrials.gov